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Paracrine Hedgehog (Hh) signaling, in which tumor-derived Hh ligands activate stromal cells, has been implicated in the
development and progression of many cancers. Recent data suggest that Hh-targeted therapeutics exert direct effects
on host cells, thus interrupting a ”vicious cycle” to bone metastasis that involves osteoblasts, osteoclasts, and tumor cells.

Hedgehog (Hh) signaling is recognized
to contribute to the development and
progression of many cancers.1 During
embryonic development, Hh signaling
is critical for proper cellular differentiation. However, the Hh pathway is largely
silenced postnatally, making it an attractive anticancer target. In its resting state,
the receptor Patched (PTCH) inhibits the
pathway transducer Smoothened (SMO).
Binding of the ligands Indian, Desert, or
Sonic Hh (SHH) to PTCH releases SMO,
resulting in the activation of downstream
signaling (which involves GLI transcription factors) that mediates increased cellular proliferation and survival.
To date, 7 small molecule inhibitors of
SMO have entered clinical trials, while compounds targeting additional components
of the Hh pathway are under preclinical
development.1 As targeted therapies, SMO
antagonists have demonstrated safety and
efficacy in tumors with ligand-independent
Hh pathway activation due to mutations in
PTCH or SMO. Following these encouraging clinical results, vismodegib has been
granted FDA approval for the treatment of
basal cell carcinoma, although it is important to note that even responsive tumors
may develop resistance.2 The clinical efficacy of SMO antagonists in other tumor
types remains unclear, with some trials suspended due to the absence of clinical benefit.
This apparent inefficacy may be attributed
to the fact that the pro-tumorigenic effects

of Hh signaling in many settings is a result
of enhanced paracrine stimulation of host
components, rather than of direct effects on
malignant cells.
For several years, paracrine Hh signaling between tumors and stroma has been
recognized to support malignant growth.3
Our recent Cancer Research report4 and
those of others5–8 suggest that Hh-targeted
therapeutics may be particularly efficient
for tumors that arise within the bone
(i.e., multiple myeloma, osteosarcoma) or
metastasize to bones (i.e., breast, prostate
and lung cancer) due to effects on host
cells within this microenvironment. The
bone is a preferred site of tumor growth,
containing abundant growth factors such
as transforming growth factor β (TGFβ)
and bone morphogenic proteins (BMPs)
stored within the mineralized matrix and
released by bone-resorbing osteoclasts
(OCs). In turn, tumor-derived factors
such as osteopontin, PTHrP and interleukin-6 (IL-6) deregulate bone remodeling,
resulting in excessive activation of OCs
generating osteolytic lesions and/or boneforming osteoblasts (OBs) causing osteoblastic lesions. This self-perpetuating
cycle of tumor growth and bone abnormalities is known as the “vicious cycle.”9
Similar tumor-supporting cycles involving stromal and immune cells as well as
components of the extracellular matrix
have also been described for tumors developing in non-bone anatomical locations.

Our data suggest that paracrine Hh
signaling can increase tumor growth
through direct actions on stromal cells
including OCs (Fig. 1).4 We first demonstrated that genetic deletion or pharmacological antagonism of SMO inhibited
the differentiation and bone resorption
function of OCs, revealing a previously
undescribed cell-autonomous role for
Hh signaling in cells of the OC lineage.
Conversely, mice with constitutive Hh
pathway signaling due to the heterozygous loss of the inhibitory receptor PTCH
(Ptch +/− ) exhibited increased OC activity.
Further, we demonstrated that the specific enhancement of Hh signaling in host
cells resulted in increased subcutaneous
growth and bone-metastatic potential in
Ptch+/− mice, attributed to both the mesenchymal and hematopoietic compartments. Together, these data demonstrate
that regulated Hh signaling is critical for
normal OC maturation and function and
that enhanced Hh signaling in host cells
promotes tumor growth.
Downstream activating mutations or
alterations that prevent the binding of
SMO to PTCH render a significant portion of tumors resistant to SMO antagonists, limiting their clinical use. As such,
MDA-MB-231 human breast cancer cells
are resistant to direct cytotoxic effects by
SMO antagonists due to undetectable
SMO expression. This system allowed us
to precisely examine the effects of SMO
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Figure 1. Tumor cell production of the Hh ligand SHH stimulates the vicious cycle of bone metastasis. Tumor-derived SHH acts in a paracrine manner
to stimulate Hh signaling in host cells within the bone microenvironment. Hh signaling in bone marrow stromal cells augments production of factors
that promote tumor growth including, but not limited to, interleukin-6 (IL-6). SHH also induces osteoblastic commitment. Osteoblasts express RANK
ligand (RANKL), which binds to RANK on myeloid progenitors leading to the formation of multinucleated, bone-resorbing osteoclasts. Hh signaling
also exerts cell-autonomous effects on osteoclast differentiation and function. Finally, osteoclastic bone resorption releases growth factors such as
transforming growth factor β (TGFβ) and bone morphogenic proteins (BMPs) from the mineralized matrix, further enhancing tumor growth and survival. This creates a ‘vicious cycle’ in which tumor-derived factors such as SHH, along with other known osteolytic factors (gray box), deregulate bone
remodeling (solid black lines), while stimulating the production of pro-tumorigenic factors (dashed gray lines). This self-perpetuating cycle results in
increased tumor burden and bone destruction.

inhibitors on the tumor microenvironment. Interestingly, MDA-MB-231 cells
express high levels of the ligand SHH, yet
cannot respond to it in an autocrine fashion. We hypothesized that the production
of SHH by tumor cells would promote a
paracrine signaling pathway and stimulate Hh signaling in host cells. Therefore,
targeting SMO specifically within stromal
cells would effectively block the supply of
pro-tumorigenic growth factors. Indeed,
the SMO inhibitor LDE225 (which is
currently being tested in Phase II clinical trials) decreased the growth of resistant MDA-MB-231 cells in vivo. We
demonstrated that tumor-derived SHH
induced paracrine signaling in bone marrow stromal cells, resulting in increased
expression of the pro-tumorigenic
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cytokine IL-6. Accordingly, knockdown
of SHH in MDA-MB-231 cells resulted
in decreased tumor growth in vivo. Taken
together, these data provide evidence that
Hh-targeted agents may offer a clinical
benefit even in the context of Hh resistant
tumors. In this scenario, SMO inhibitors
would act on host cells, rendering them
unresponsive to tumoral Hh ligands and
changing the microenvironment into one
that is less supportive of tumor growth.
Our data, along with that of several
other groups,5–8 underscore the beneficial
effects resulting from Hh inhibition in
host cells. The Hh pathway has also been
implicated in the maintenance of a “cancer stem cell” compartment, implying
that Hh inhibitors may exert substantial
effect specifically on this rare, long-lived
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sub-population.10 Altogether, these observations suggest that the benefits of Hh
inhibition may be most apparent in an
adjuvant setting, in which the prevention
of recurrence or metastasis follows the
eradication of the primary tumor with
conventional or targeted therapeutics. We
propose that Hh-targeted therapeutics may
be particularly attractive for the treatment
and prevention of bone metastasis, as they
effectively interrupt the “vicious cycle” of
pro-tumor interactions between OB, OC
and tumor cells. In ongoing preclinical
and Phase II clinical studies, we are exploring the effects that SMO antagonists exert
in preventing the survival and expansion of
residual bone-marrow disseminated tumor
cells (DTCs) in patients with high-risk
localized breast cancer.
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